Project: Targeting OsteoArthritis with Senolytic and anti-Inflammatory peptide-loaded nanopharmaceuticals
| Acronym | OASIs (Reference Number: EURONANOMED2021-156) |
| Duration | 01/01/2022 - 31/12/2024 |
| Project Topic | Osteoarthritis (OA) is the most common form of arthritis and a leading cause of pain and disability worldwide. Current treatments are limited to symptom relief. There is an urgent need to develop innovative therapeutic strategies that aim to restore joint function for the benefit of millions of people worldwide. Major limitations relate to the complexity of the underlying pathogenic mechanisms for the different clinical phenotypes, and even more for the unmet need for efficient delivery strategies. OA treatment might be attained by personalizing care, accompanied by the development of targeted therapeutics that can successfully be delivered making use of nanotechnology. We aim to develop innovative nanopharmaceuticals based on the association of peptides that target senescence and inflammation to nanoemulsions that can safely be administered to the synovial joint via intra-articular injection, and provide sustained and long-lasting, symptom and structure modification, for the enhanced treatment of OA. Interfering peptides targeting senescent cells can modulate tissue regeneration and response to injury. Anti-inflammatory peptides from biological venoms have shown to reduce inflammation and pain. In this proposal we will develop new combinatorial targeted therapies by loading these peptides into biocompatible and biodegradable, safe-by-design and versatile, lipid nanoemulsions. The most promising combinations will be assessed in vitro, ex vivo and in vivo. Optimization of critical formulation parameters, nuclear imaging tracking, and pharmacokinetic studies, will allow to select a nanopharmaceutical composition for preclinical evaluation. The results obtained in this proposal will help us to make state-of-the-art advances in order to successfully advance our research to the clinic. Attention to critical manufacturing processes, exploitation, dissemination and managerial activities will ensure translatability of the candidate nanopharmaceuticals. |
| Website | visit project website |
| Network | EuroNanoMed III |
| Call | Joint Transnational Call (2021) |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Fundación Instituto de Investigación Sanitaria de Santiago de Compostela | Coordinator | Spain |
| 2 | Fundación Profesor Novoa Santos | Partner | Spain |
| 3 | State Research Institute Centre for Innovative Medicine | Partner | Lithuania |
| 4 | V-NANO | Partner | France |
| 5 | NATIONAL INSTITUTE OF RESEARCH AND DEVELOPMENT FOR TECHNICAL PHYSICS | Partner | Romania |